Contrast-Induced Nephropathy and the Vascular Patient

Angiology

Volumn 61, Issue 8, 2010, Pages 721-723

  Paraskevas, Kosmas I ^a   Giannoukas, Athanasios D ^a   Kotsikoris, Ioannis ^a   Mikhailidis, Dimitri P ^b  

^a RED CROSS HOSPITAL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM; CYSTATIN C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; HEART CATHETERIZATION; HUMAN; KIDNEY DISEASE; NOTE; RADIOGRAPHY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CONTRAST MEDIA; CYSTATIN C; HEART CATHETERIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES;

EID: 78049419934     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710379110     Document Type: Editorial

References (31)

1. Ishibashi Y, Yamauchi M, Musha H, et al. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing coronary catheterization. Angiology. IN PRESS.
2. Shaker O, El-Shehaby A, El-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology. IN PRESS.
3. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol. 2004;183(6):1673-1689.
4. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461-1471.
5. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14): 1799-1806.
6. Brady HR, Singer GG. Acute renal failure. Lancet. 1995; 346(8989):1533-1540.
7. Tepel M, van der Giet M, Schwarzfeld C, Lauder U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180-184.
8. Paraskevas KI, Bessias N, Perdikides TP, Mikhailidis DP. Statins and venous thromboembolism: a novel effect of statins? Curr Med Res Opin. 2009;25(7):1807-1809.
9. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol. 2008;6(4):237-239.
10. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74(5):818-826.
11. Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy—Part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010;44(4):241-251.
12. Beri A, Contractor T, Khasnis A, Thakur R. Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect? Am J Cardiovasc Drugs. 2010;10(3):155-164.
13. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention. Curr Vasc Pharmacol. 2009;7(3):264-266.
14. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004; 62(4):273-278.
15. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118(8):843-849.
16. Zhao JL, Yang YJ, Zhang YH, You SJ, Wu YJ, Gao RL. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol. 2008;126(3):435-436.
17. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101(3):279-285.
18. Yoshida S, Kamihata H, Nakamura S, et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol. 2009;54(2):192-198.
19. Kandula P, Shah R, Singh N, Markwell SJ, Bhensdadia N, Navaneethan SD. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology (Carlton). 2010;15(2):165-170.
20. Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 104(4):519-524.
21. Alnaeb ME, Youssef F, Mikhailidis DP, Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006;57(1):65-71.
22. Writing Group Members. Lloyd-Jones D, Adams RJ, Carnethon M, et al;. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the America Heart Association. Circulation. 2010;121(7):e46-e215.
23. Proceedings of a Centers for Disease Control and Prevention Expert Panel Workshop: developing a comprehensive public health strategy for preventing the development, progression, and complications of chronic kidney disease. March 2007. Am J Kidney Dis. 2009;53(3 suppl 3):S1-S125.
24. Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2010;55(1 suppl 1):S1-S420, A6-A7.
25. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119(13):1728-1735.
26. Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother. 2010;11(5):723-730.
27. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728-734.
28. Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-767.
29. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
30. Spargias K, Adreanides E, Demerouti E, et al. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2009;120(18):1793-1799.
31. Hernández F, Mora L, García-Tejada J, et al. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty. Rev Esp Cardiol. 2009;62(12):1373-1380.